ÂÜŔňÂŇÂ×

Reporting to the Controller, this individual will serve as an integral team member with exposure to multiple facets of business operations.  The Senior Accounting Manager will manage various general accounting and financial reporting processes to ensure timely and accurate financial information in accordance with US GAAP. Key duties include leading the monthly close process, leading the quarterly and annual SEC filings, performing balance sheet account analysis, supporting external audits, improving processes and creating efficiencies, and handling management requests and special projects. The successful candidate will have a strong background in accounting and finance and the ability to work collaboratively with cross-functional teams possessing a “can do” attitude and a willingness to roll up their sleeves to ensure timely and accurate delivery of the work product required from the Accounting function.

Elicio is a growing organization based out of Boston, Massachusetts with additional staff functioning in a virtual based environment from the Greater Boston area and throughout the United States. 

This position allows for hybrid work with regular weekly onsite attendance.

Major Duties/Responsibilities

• Leads the monthly accounting close process

• Reviews journal entries and reconciliations prepared by accounting team members

• Obtains and maintains a thorough understanding of the financial reporting and general ledger structure

• Leads the quarterly and annual SEC filings (10-Q’s and 10-K’s) and other filings as required

• Assists in development and implementation of policies and procedures for accounting activities and functions

• Supports the engagement with external auditors for annual audits, quarterly financial reviews, and internal controls testing

• Other projects, internal reports and request, integrations, and duties, as needed

• Promote a culture of collaboration, cooperation, cross functional inclusion, execution excellence, effective communication and cross-functional problem-solving to become a high-performing team.

Education & Professional Experience

Required:

• Degree in Business, Accounting or Finance, Master's degree preferred. CPA required.
• 7+ years of relevant accounting experience in biotech or life sciences industry. Prior public accounting experience preferred
• NetSuite and Workiva experience preferred
• Prior experience with SEC reporting related to 10-Q, 10-K and other filings
• Strong working knowledge in general ledger and GAAP

Skills:

• Excellent communication skills, with the ability to collaborate effectively with cross-functional teams
• Strong team player with the ability to work in a fast-paced environment, manage competing priorities, while filling gaps as needed
• Ability to multi-task, work under pressure, pay attention to detail and meet deadlines

Working Conditions: Busy office/laboratory environment with frequent deadlines and interruptions

Travel: Travel is not required

Physical Requirements: Subject to periods of sitting or standing, vision is required to monitor data.

About Elicio Therapeutics

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (AMP) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.  The AMP platform emerged from the laboratories of Darrell Irvine, Howard Hughes Investigator and Professor of Biomedical Engineering in the Koch Institute of Integrative Cancer Research at MIT.  For more information, please visit .

About the Amphiphile Platform

Elicio Therapeutics’ proprietary Amphiphile (“AMP”) platform delivers investigational immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate, and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio has observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes our AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based upon preclinical studies. Elicio’s AMP platform, originally developed at the Massachusetts Institute of Technology has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships. The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the bloodstream, as it travels to lymphatic tissue. In preclinical models, Elicio has observed lymph node-specific engagement driving immune responses of increased magnitude, function and durability.